Focused On-demand Library for Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Protein phosphatase subunit G5PR; Rhabdomyosarcoma antigen MU-RMS-40.6A/6C

Alternative UPACC:

Q969Q6; B4DEN7; D3DS97; D3DS98; Q5GJ55; Q5GJ56; Q6P4G2; Q86TZ3; Q9NWR9


Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma, also known as Protein phosphatase subunit G5PR and Rhabdomyosarcoma antigen MU-RMS-40.6A/6C, plays a pivotal role in various cellular processes. It is involved in the regulation of MCM3AP phosphorylation, acts as a negative regulator of ABCB1 expression and function, and may contribute to the activation-induced cell death of B-cells. This protein's multifaceted role in biological systems makes it an intriguing subject for scientific inquiry.

Therapeutic significance:

Linked to Myoectodermal gonadal dysgenesis syndrome and Spermatogenic failure 36, Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma's involvement in these diseases highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies, offering hope for patients suffering from these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.